grant
Targeting macrophage reprogramming in glioblastoma
Organization CLEVELAND CLINIC LERNER COM-CWRULocation CLEVELAND, UNITED STATESPosted 1 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY202521+ years oldAPRF proteinAcute-Phase Response FactorAdultAdult HumanAffectBlood monocyteBrain CancerCCL2CCL2 geneCCL7CCL7 geneCell BodyCell Communication and SignalingCell Culture TechniquesCell SignalingCellsChemokine, CC Motif, Ligand 2ClinicalCombined Modality TherapyCytometryDataData SetDiagnosisDiseaseDisorderEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExhibitsFamilyFeesFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryG Protein-Complex ReceptorG Protein-Coupled Receptor GenesG-Protein-Coupled ReceptorsGEM modelGEMM modelGPCRGeneralized GrowthGeneticGenetically Engineered MouseGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrowthIL6-response factorImmunofluorescenceImmunofluorescence ImmunologicImmunotherapeutic agentImpairmentIn VitroInfiltrationIntracellular Communication and SignalingKO miceKnock-out MiceKnockout MiceKnowledgeLIF-response factorMARCMCAFMCP-1MCP-3MCP1MCP3MacrophageMalignant Tumor of the BrainMalignant neoplasm of brainMarrow monocyteMediatingMiceMice MammalsModelingMolecularMonocyte Chemoattractant Protein-1Monocyte Chemotactic Protein-1Monocyte Chemotactic and Activating FactorMonocyte Chemotactic and Activating ProteinMonocyte Chemotactive and Activating FactorMonocyte Secretory Protein JEMultimodal TherapyMultimodal TreatmentMurineMusMyeloid CellsMφNC28Neuroglial NeoplasmNeuroglial TumorNull MousePDX modelPathway interactionsPatient derived xenograftPatientsPhenotypePopulationProcessProteomicsRNA SeqRNA sequencingRNAseqReceptor ProteinResearch SpecimenRoleSCYA2SCYA7SamplingSignal Transducer and Activator of Transcription 3Signal TransductionSignal Transduction SystemsSignalingSmall Inducible Cytokine A2Solid NeoplasmSolid TumorSpecimenStat3 proteinStem Cell likeSystemTCGATestingThe Cancer Genome AtlasTherapeuticTimeTissue GrowthTranslational ResearchTranslational ScienceTumor PromotionTumor-associated macrophagesValidationadulthoodbiological signal transductioncancer microenvironmentcancer progressioncell culturecell culturescombination therapycombined modality treatmentcombined treatmentdruggable targetepigeneticallyflow cytophotometrygain of functiongenetically engineered mouse modelgenetically engineered murine modelglial-derived tumorglioblastoma multiformeimmune drugsimmune-based therapeuticsimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentin vivoinhibitorinnovateinnovationinnovativeloss of functionmonocytemouse modelmulti-modal therapymulti-modal treatmentmurine modelneoplasm progressionneoplastic progressionneuroglia neoplasmneuroglia tumornew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachontogenypathwaypatient derived xenograft modelperipheral bloodpharmacologicpre-clinicalpre-clinical trialpreclinicalpreclinical trialprogenitor capacityprogenitor cell likeprogenitor-likeprogramsreceptorscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolespongioblastoma multiformestem cell characteristicsstem-likestemnesstherapeutic targettranscriptome profilingtranscriptome sequencingtranscriptomic profilingtranscriptomic sequencingtranscriptomicstranslation researchtranslational investigationtranslational studytumortumor microenvironmenttumor progressionvalidations
Description preview
Project Summary
Glioblastoma is the most lethal form of primary brain cancer in adults with a median survival of approximately
14-16 months following diagnosis. In contrast to glioma cells, components of the tumor microenvironment (TME)
of glioblastoma are genetically stable and are considering as the promising therapeutic targets. Tumor-…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click